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We examined the incidence, risk factors, treatments, and clinical outcomes of post-transplantation lym-
phoproliferative disorder (PTLD) after unmanipulated haploidentical (haplo) hematopoietic stem cell trans-
plantation (HSCT) in 1184 patients between 2006 and 2012. Age-, transplantation timee, and transplantation
durationematched controls were randomly selected from the same cohort. Forty-ﬁve patients experienced
PTLD. The median time from HSCT to PTLD occurrence was 61 (range, 33 to 360) days and the 1-year cu-
mulative incidence of total PTLD after haplo-HSCT was 3.0%. In multivariate analysis, a lower absolute count of
CD8þ T lymphocytes at day 30, a lower absolute count of immunoglobulin M at day 30, and cytomegalovirus
DNAemia after HSCT were signiﬁcantly associated with higher risk of PTLD. The 2-year probability of overall
survival (OS) after HSCT was 42.8%, which was comparable between the probable PTLD and the proven PTLD
patients. Patients who received rituximab-based therapy had signiﬁcantly better 2-year OS (48.2% versus
13.2%, P ¼ .02). Thus, we were able to identify individuals at a high risk of developing PTLD after unma-
nipulated haplo-HSCT. Rituximab-based therapy can help to improve the outcomes of PTLD patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic (allo) hematopoietic stem cell transplantation
(HSCT) is an effective treatment for hematological malig-
nancies; many patients are cured or achieve long-term
remission. However, Epstein-Barr virus (EBV)erelated post-
transplantation lymphoproliferative disorder (PTLD) after
allo-HSCT can seriously hinder patient survival [1,2]. Baker
et al. [3], Uhlin et al. [4], and Styczynski et al. [5] reported the
incidence of PTLD to be 1.28%, 4%, and 3.22%, respectively. In
addition, PTLD is associated with a mortality rate as high asdgments on page 2190.
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ty for Blood and Marrow Transplantation.50% to 90% [5,6]; therefore, this complication warrants
greater attention.
Several risk factors may be associated with the develop-
ment of PTLD after allo-HSCT, including HLA disparity (un-
related donor or haploidentical donor), in vitro T
celledepleted antithymocyte globulin (ATG) or anti-CD3
antibody in the conditioning regimen, and grade II to IV
acute graft-versus-host disease (GVHD) [7-12]. Some authors
also report that patients with more risk factors have higher
risk of PTLD [12]. Moreover, compared with other types of
HSCT recipients, haploidentical HSCT (haplo-HSCT) re-
cipients may have more risk factors for PTLD, such as HLA
disparity and the use of ATG, which is an important
component of GVHD prophylaxis. Because of the rapid pro-
gression and poor prognosis of PTLD, recognizing high-risk
patients after haplo-HSCT is critical. However, few studies
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haplo-HSCT recipients. In addition, although some authors
report immune reconstitution is associated with PTLD after
solid-organ transplantation [13], the association between
immune reconstitution and haplo-HSCT is unknown.
Furthermore, the incidence, treatments, and clinical out-
comes of PTLD in unmanipulated haplo-HSCT recipients are
also unknown.
Therefore, this study used both a retrospective cohort
study design and nested case-control approach to identify
the incidence, risk factors, treatments, and clinical outcomes
of PTLD after unmanipulated haplo-HSCT.PATIENTS AND METHODS
Patients
A total of 1184 consecutive patients underwent unmanipulated haplo-
HSCT between 2006 and 2012 at the Peking University Institute ofTable 1
Patient Characteristics
Characteristic PTLD C
Sex
Male 28
Female 17
Age at HSCT, median (range), yr 25
Year of HSCT
<2010 8
2010 37
Diagnosis
AML 19
ALL 21
MDS 2
CML 2
SAA 1
Status at HSCT
Standard risk 42
High risk 3
Time from diagnosis to HSCT, median (range), d 210
Donor-recipient blood type
Matched 27
Major mismatched 11
Minor mismatched 4
Major and minor mismatched 3
Donor age, median (range), yr 43
Donor-recipient gender
Male-male 18
Female-female 11
Male-female 6
Female-male 10
Donor-recipient relation
Mother-child 13
Father-child 18
Sibling-sibling 10
Child-parent 2
Other 2
Pre-HSCT EBV status, donor/recipient
Positive/positive 40
Positive/negative 2
Negative/positive 2
Negative/negative 1
HLA disparity
1 Locus 4
2 Loci 41
MNC, 108/kg 8.68
Total lymphocyte absolute count, median (range), 106/kg 204.22
CD34þ cell absolute count, median (range), 106/kg 1.95
CD3þ cell absolute count, median (range), 106/kg 138.86
CD4þ cell absolute count, median (range), 106/kg 80.05
AML indicates acute myeloid leukemia; ALL, acute lymphoid leukemia; MDS, myelo
anemia; MNC, mononuclear cells.
The criterion for statistical signiﬁcance was P < .05.
* Groupmatching criteria included age at the time of HSCT (5 years), time of the
3 controls were randomly selected from the same cohort when PTLD occurred (“rHematology (Beijing, China). Medical records maintained at the institution
were the primary data source for the current study. Patients who had
developed PTLD after haplo-HSCT were considered PTLD cases. For each
PTLD case, 3 controls were randomly selected from the same cohort when
PTLD occurred (ie, “risk-set sampling”) [14] and were matched according to
the following criteria: age at the time of HSCT (5 years), time of the HSCT
(4 months), and transplantation duration (3 months). A total of 45 PTLD
cases and 135 matched controls were included in the analyses; the char-
acteristics of the cases are summarized in Table 1. The study protocol was
approved by the ethics committee of Peking University People’s Hospital.
Informed consent was obtained in accordance with the Declaration of Hel-
sinki. Eight patients were previously reported in 2009 [15], and all of these
previously reported patients were enrolled and further followed in this
study.
Transplantation Procedure
The conditioning therapy consisted of cytarabine (4 g/m2) intravenously
on days 10 to 9, busulfan (3.2 mg/kg/day) intravenously on days 8
to 6, cyclophosphamide (1.8 g/m2/d) intravenously on days 5 to 4,
semustine (250 mg/m2) orally once on day 3, and ATG (1.5 to 2.5 mg/kg/d;ases* (n ¼ 45) Controls* (n ¼ 135) P Value
(62.2) 80 (59.3) .725
(37.8) 55 (40.7)
(3-49) 27 (3-48) .111
(17.8) 24 (17.8) 1.000
(82.2) 111 (82.2)
(42.4) 59 (43.7) .328
(46.7) 52 (38.5)
(4.4) 11 (8.1)
(4.4) 13 (9.6)
(2.2) 0 (0.0)
(93.3) 118 (87.4) .273
(6.7) 17 (12.6)
(93-1500) 191 (70-4380) .711
(60.0) 78 (57.8) .139
(24.4) 21 (15.6)
(8.9) 30 (22.2)
(6.7) 6 (4.4)
(16-61) 38 (14-63) .015
(40.0) 42 (31.1) .172
(24.4) 21 (15.6)
(13.3) 35 (25.9)
(22.2) 37 (27.4)
(28.9) 30 (22.2) .100
(40.0) 37 (27.4)
(22.3) 48 (35.6)
(4.4) 18 (13.3)
(4.4) 2 (1.5)
(88.9) 118 (87.4) .298
(4.4) 7 (5.2)
(4.4) 1 (.7)
(2.2) 9 (6.7)
(8.9) 9 (6.7) .740
(91.1) 126 (93.3)
(5.69-17.15) 8.06 (4.2-13.78) .278
(109.28-762.10) 243.30 (42.34-507.62) .037
(.40-4.80) 2.23 (.35-9.26) .200
(63.86-702.84) 164.66 (22.89-379.08) .027
(29.80-157.92) 94.71 (10.65-214.03) .380
dysplastic syndromes; CML, chronic myeloid leukemia; SAA, severe aplastic
HSCT (4months), and transplantation duration (3months). For each case,
isk-set sampling”).
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patients received granulocyte colony stimulating factoremobilized, fresh,
and unmanipulated bone marrow cells plus peripheral blood stem cells. In
instances of ABOmajor blood group incompatibility, red cells were removed
from bone marrow cells by density gradient sedimentation with Hespan
(B. Braun Medical Inc, Irvine, CA), according to the manufacturer’s
instructions. Surface markers of the cells in graft were determined by 2- or
3-color staining using monoclonal antibodies speciﬁc for CD34, CD3, CD4,
and CD8 cells, essentially as described by Liu et al. [16]. All patients received
cyclosporin A, mycophenolate mofetil, and short-term methotrexate for
GVHD prophylaxis [17].
Donor Selection
Low-resolution DNA techniques were used to determine HLA-A and
HLA-B status, and high-resolution techniques were used for HLA-DRB1
typing. All donor-recipient pairs were typed at the HLA-A, HLA-B, and
HLA-DR loci at our institute. Each patient with a haploidentical donor
received stem cells from a familymember who shared 1 HLA haplotypewith
the patient but differed to a variable degree for the HLA-A, HLA-B, and
HLA-D antigens of the haplotype not shared. Besides each donor-recipient
pair, HLA typing was performed for parents and offspring and strictly
analyzed to guarantee a true haploid genetic background.
Deﬁnitions
Diagnosis of GVHD was in accordance with accepted international
criteria [18]. The diagnosis of PTLD was deﬁned as proven or probable ac-
cording to the published deﬁnition [19,20]. Proven PTLD was diagnosed if
EBV were detected in a specimen obtained from an organ by biopsy or other
invasive procedure according to a test with appropriate sensitivity and
speciﬁcity together with symptoms and signs from the affected organ.
Probable PTLD was deﬁned as signiﬁcant lymphoadenopathy or other end-
organ disease accompanied by a positive EBV-DNA blood load in the
absence of other etiologic factors and established diseases. Patients were
classiﬁed as high-risk if they were in more than third complete remission
(CR3) of acute leukemia, not in remission, had high-risk cytogenetics, such
as t(9;22) or t(4;11), and chronic myelogenous leukemia beyond the ﬁrst
chronic phase; the other patients were classiﬁed as standard-risk [15,17].
Real-time quantitative PCR for the detection of cytomegalovirus (CMV) DNA
and EBV DNA was used to detect CMV DNAemia and EBV DNAemia in
plasma, and virus DNAemia1103 genome copies/mLwas considered as a
positive PCR. Complete remission (CR) of PTLD was deﬁned as the disap-
pearance of all clinical signs of PTLD conﬁrmed by physical examination and
imaging studies. Overall survival (OS) was deﬁned as the time from trans-
plantation to death from any cause.
Statistical Analysis
Data were analyzed in April 2013. In the cohort analysis, competing risk
analysis was performed to calculate the cumulative incidence of PTLD [21],
treating death without PTLD as the competing event for PTLD. The time to
risk was computed from the date of haplo-HSCT to the date of PTLD onset,
last contact, or death, whichever came ﬁrst. The log-rank test was used to
compare the various subpopulations.
In the nested case-control analysis, continuous variables were compared
using the Mann-Whitney U-test, and categorical variables were compared
using chi-square test and Fisher’s exact test. Survival probabilities were
estimated using the Kaplan-Meier method. Hazard ratios (HR) for PTLD after
haplo-HSCT were estimated from univariate andmultivariate Cox regression
analyses. Factors included in the regression model included recipient sex,
age, underlying disease, disease status, HLA disparity, donor age, donor-
recipient sex matched, donor and recipient EBV serostatus, cells absolute
counts for infusion (total lymphocyte count, CD3þ cells count, CD4þ cells
count, CD34þ cells count, using the median as cut-off point), acute GVHD
(aGVHD) after HSCT, CMV DNAemia after HSCT, and immune reconstitution
after HSCT (ie, absolute counts of cell subsets and Ig at day 30 after HSCT,
using the median as a cut-off). All of the factors with P< .10 in the univariate
analysis were included in the multivariate regression, and P < .05 was
considered to be statistically signiﬁcant. Data analyses were primarily con-
ducted using SPSS (SPSS Inc., Chicago, IL), while the R software package
(version 2.6.1; http://www.r-project.org) was used for competing risk
analysis.
RESULTS
PTLD Characteristics
Forty-ﬁve patients were diagnosedwith PTLD after haplo-
HSCT. PTLD was proven by biopsy in 12 cases (26.7%) and the
remaining 33 (73.3%) caseswere considered probable disease
(Supplementary Table 1). Themedian time fromHSCT toPTLDoccurrence was 61 (range, 33 to 360) days. The cumulative
incidences of total and proven PTLD 1 year after haplo-HSCT
were 3.0% (95% conﬁdence interval [CI], 1.8% to 4.2%) and
1.0% (95% CI, .3% to 1.7%), respectively. Forty-three PTLD pa-
tients hadEBVDNAemia, and themedianviral loadwas 1.69
104 genome copies/mL. Themedian time between ﬁrst test of
EBV viremia and symptom onset was 2 days (range, 34
to þ18 days). Nineteen patients showed extranodal involve-
ment and 9 of them showed multiorgan involvement.
Pre-HSCT Parameters and PTLD
The PTLD group had signiﬁcantly lower absolute counts of
total lymphocytes (P ¼ .037) and CD3þ cells in grafts (P ¼
.027); however, the absolute counts of CD34þ and CD4þ cells
in the grafts were comparable between groups. Other pre-
HSCT parameters were comparable between the PTLD case
and control groups (Table 1).
Post-HSCT Complications and PLTD
There was a trend for higher CMV DNAemia in the PTLD
group (86.7% versus 72.6%, P ¼ .055). The occurrences of
grade II to IV and III to IV aGVHD were comparable between
the PTLD case and control groups (Table 2).
Immune Reconstitution after Haplo-HSCT and PTLD
Compared with the control group, the PTLD group had
signiﬁcantly lower absolute counts of total lymphocytes (P ¼
.004), CD19þ (P¼ .005), CD3þ (P< .001), CD4þ (P< .001), and
CD8þ cells (P < .001) at day 30 after HSCT. The absolute level
of IgM at day 30 after HSCTwas also signiﬁcantly lower in the
PTLD group (P ¼ .01) (Table 2).
Risk Factors for PTLD after Haplo-HSCT
In multivariate analysis, a lower absolute count of CD8þ T
lymphocytes at day 30, a lower absolute count of IgM at day
30, and CMV DNAemia after haplo-HSCT were signiﬁcantly
associated with a higher risk of PTLD (Table 3). The risk of
PTLD was higher in patients who have 2 (HR, 6.40, 95% CI, .87
to 47.11; P ¼ .068) or 3 (HR, 11.45; 95% CI, 1.43 to 91.85; P ¼
.022) risk factors compared to those who did not have any
risk factor after haplo-HSCT.
Treatments and Clinical Outcomes
One PTLD patient refused treatment and subsequently
died from the disease. Thirty-six patients were treated with
rituximab-based therapy (the other 8 patients did not
receive rituximab because of the economic burden). In
addition, 16 received donor lymphocyte infusion (DLI), 13
received corticosteroids, 7 received reduction of immuno-
suppression, 4 received antiviral drugs, 3 received EBV-
speciﬁc cytotoxic T lymphocyte (CTL) infusion, and 1
received chemotherapy. Twenty-three patients received
combination treatments (2 types of treatment). Thirty-
three PTLD patients achieved CR after treatments; the CR
rate was comparable between probable and proven PTLD
cases (75.8% versus 66.7%, P ¼ .705). The patients who
received rituximab-based therapy have a higher CR rate
(80.6% versus 44.4%, P ¼ .043).
Twenty-two of the 45 patients are alive. The 2-year
probability of OS after HSCT was 42.8% versus 82.7% in
PTLD case and control groups (P < .001, Figure 1A). The
2-year probability of OS after HSCT was comparable between
the probable PTLD and the proven PTLD patients (43.9%
versus 32.1%, P ¼ .430, Figure 1B). The patients who received
rituximab-based therapy had a better 2-year probability of
Table 2
Characteristics of GVHD, Infection, and Immune Reconstitution between PLTD Cases and Controls
Characteristic PTLD Cases* (n ¼ 45) Controls* (n ¼ 135) P Value
Transplantation-related complication by type
Acute GVHD
Grades II-IV 18 (40.0) 38 (28.1) .137
Grades III-IV 1 (2.2) 13 (9.6) .195
Infections at 100 days after HSCT
CMV DNAemia 39 (86.7) 98 (72.6) .055
Immune reconstitution, 30 d after HSCT, median (range)
Total lymphocyte absolute count, 109/L .21 (.04-.85) .28 (.03-4.46) .004
CD19þ cell absolute count, 109/L .0040 (.0001-.0158) .0050 (.0001-.0508) .005
CD3þ cell absolute count, 109/L .0350 (.0006-.4251) .0997 (.0006-4.0486) <.001
CD4þ cell absolute count, 109/L .0047 (.0000-.0886) .0234 (.0002-.3172) <.001
CD8þ cell absolute count, 109/L .0114 (.0000-.4207) .0280 (.0003-.3355) <.001
IgG g/L 7.54 (.83-24.7) 8.19 (3.31-24.2) .341
IgA g/L .55 (.10-7.19) .68 (.22-2.83) .079
IgM g/L .31 (.08-.71) .43 (.04-2.09) .010
PLTD indicates post-transplantation lymphoproliferative disorder.
The criterion for statistical signiﬁcance was P < .05.
* Groupmatching criteria included age at the time of HSCT (5 years), time of the HSCT (4months), and transplantation duration (3months). For each case,
3 controls were randomly selected from the same cohort when PTLD occurred (“risk-set sampling”).
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could not improve the outcomes of PTLD patients (Figure 2B).DISCUSSION
In the present study, the incidence of PTLD in unmanip-
ulated haplo-HSCT recipients was 3%, which was in accor-
dance with the results of Styczynski et al. (2.86%) [5]. Poorer
immune reconstitution at day 30 after HSCT and CMV
DNAemia after unmanipulated haplo-HSCT were signiﬁ-
cantly associated with PTLD. Patients receiving rituximab-
based therapy seemed to have a better OS; however, the
survival of PTLD patients was still signiﬁcantly poorer than
that of those without PTLD after haplo-HSCT. To our knowl-
edge, this study is the ﬁrst to identify the risk factors for PTLD
after unmanipulated haplo-HSCT and report an association
between early immune reconstitution and PTLD after haplo-
HSCT.Table 3
Univariate Analysis and Multivariate Analysis of Risk Factors for PTLD after Haplo-
Variable Uni
HR
Age at HSCT (18 yr versus <18 y) .62
Sex (male versus female) .79
Underlying disease (acute leukemia versus nonacute leukemia) .93
Disease status at HSCT (high-risk versus standard-risk) .57
Donor-recipient sex (female-male versus others) .65
HLA disparity (2-3 loci versus 1 locus) .65
Donor age (median versus <median) 1.55
Pre-HSCT serological EBV mismatch (Dþ/R versus others) 1.00
TLC for infusion (median versus <median) .89
CD3þ cells count for infusion (median versus < median) .65
CD4þ cells count for infusion ( median versus <median) .75
CD34þ cells count for infusion (median versus <median) .79
aGVHD after HSCT (grade III-IV versus grade 0-II) 1.31
CMV DNAemia after HSCT (yes versus no) 6.12
TLCs at day 30 after HSCT (median versus <median) .48
CD3þ cells count at day 30 after HSCT (median versus <median) .50
CD4þ cells count at day 30 after HSCT (median versus <median) 1.06
CD8þ cells count at day 30 after HSCT (median versus <median) .35
CD19þ cells count at day 30 after HSCT (median versus <median) 1.26
IgG count at day 30 after HSCT (median versus <median) .87
IgA count at day 30 after HSCT (median versus <median) .96
IgM count at day 30 after HSCT (median versus <median) .31
D indicates donor; R, recipient; TLC, total lymphocyte count.In the present study, the absolute count of CD8þ cells at
day 30 after HSCT was lower in PTLD case group compared
with that of control group, and the multivariate analysis
showed that a lower absolute count of CD8þ cells at day 30
after HSCT increased the risk of PTLD. Although Sebelin-Wulf
et al. [13] reported that total CD8þ T cell reconstitution was
not associated with EBV reactivation in solid-organ trans-
plant recipients, Meij et al. [22] reported that patients with
insufﬁcient EBV-speciﬁc CD8þ T cell recovery were at high
risk for EBV reactivation after T celledepleted HSCT, and
impaired recovery of EBV-speciﬁc CD8þ T cells in patients
with high-level EBV reactivation may identify a subgroup at
very high risk for EBV-PTLD. This is also supported by our
earlier observations on the association between the recovery
of CMV-speciﬁc CD8þ T cells and CMV disease after unma-
nipulated haplo-HSCT [23]. Although Chang et al. [24] re-
ported that the CD8þ T cells could not fully recover at day 30
after unmanipulated haplo-HSCT, the lower absolute countHSCT
variate Analysis Multivariate Analysis
(95% CI) P Value HR (95% CI) P Value
(.29-1.30) .205
(.36-1.75) .562
(.64-1.35) .710
(.15-2.12) .399
(.26-1.64) .365
(.18-2.34) .509
(.77-3.15) .224
(.58-1.71) 1.000
(.18-4.27) .879
(.13-3.42) .614
(.22-2.62) .657
(.32-1.95) .610
(.11-15.88) .835
(1.26-29.64) .024 5.68 (1.17-27.57) .031
(.22-1.05) .066
(.13-1.96) .322
(.24-4.67) .939
(.17-.72) .004 .34 (.13-.92) .033
(.51-3.10) .621
(.30-2.53) .795
(.31-3.01) .944
(.11-.88) .027 .27 (.10-.75) .012
Figure 1. Kaplan-Meier estimates of overall survival for (A) non-PTLD and (B) PTLD probable and proven PTLD patients.
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HSCT.
We observed that CMVDNAemiawas also associatedwith
PTLD after unmanipulated haplo-HSCT. Zallio et al. [25]
observed that CMV reactivation was the most important
variable for predicting EBV reactivation and risk for PTLD after
allo-HSCT, and the author suggested that CMV reactivation
itself was related to severe immunosuppression and CMV
reactivation may, therefore, represent an indirect marker of
immunosuppression severity. On the other hand, the therapy
of CMV reactivation (such as ganciclovir) can suppress T
lymphocyte proliferation, which may translate into impaired
immune reconstitution after HSCT [26]. Thus, CMV reac-
tivation may be associated with PTLD after haplo-HSCT.
Severe aGVHD is one of the important risk factors for
PTLD after HSCT [4,12]. Our transplantation protocols, which
include a combination of the bone marrow and peripheral
blood as the source of stem cell grafts as well as the addition
of ATG to the conditioning regimen as GVHD prophylaxis,
decreased the incidence of severe aGVHD; a lower incidence
of severe aGVHD may decrease risk of PTLD. However, ATG
may also increase the risk of PTLD, and haplo-HSCT re-
cipients who did not receive ATG may have a lower risk of
PTLD. Combined depletion of both T and B cells with the
anti-CD52 monoclonal antibodies has been reported to
confer a much smaller PTLD risk (up to 1.3%) [27]. Kanakry
et al. [28] reported that no cases of PTLD occurred during theFigure 2. KaplaneMeier estimates of overall survival for PTLD patients treated with (
rituximab alone versus DLI alone: P ¼ .015; rituximab alone versus DLI plus rituximaﬁrst year after allo-HSCT using post-transplantation cyclo-
phosphamide (PTCy), even in high-risk alternative donor
transplantations. In addition, Tischer et al. [29] compared the
viral infection between haplo-HSCT settings with and
without ATG (ie, PTCy group). Twenty-ﬁve percent of the
patients in the ATG group but no patient in the PTCy group
developed PTLD, which suggests that by preserving antiviral
immunity and allowing fast immune recovery of CD4þ Tcells,
the approach using PTCy may be well suited to handle the
important issue of PTLD after haplo-HSCT [29]. Thus, how to
balance the risk of GVHD and PTLD after haplo-HSCT using
ATG should be further studied.
Previous studies also reported several risk factors for
PTLD, such as younger age and serological EBV mismatch
(donor positive/recipient negative) [7-12]. However, none of
these factors were associated with PTLD after haplo-HSCT in
the present multivariate analysis. Dharnidharka et al. [30]
reported that younger patients (<18 years) have a higher
risk of PTLD. However, Xiong et al. [31] reported that EBV
seroprevalence became more than 50% before age 3 in
Chinese children, and it exceeds 90% after age 8, which may
partially account for the weak association between age and
PTLD in the present study. Because of the high prevalence of
EBV infection in China [32], most patients have EBV-speciﬁc
antibodies and we also could not further identify the inﬂu-
ence of serological EBV mismatch on PTLD after unmanipu-
lated haplo-HSCT in the present study.A) rituximab- and nonerituximab-based therapy; (B) rituximab  DLI therapy,
b: P ¼ .036; rituximab versus non-rituximab/non-DLI: P ¼ .062.
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HSCT was also signiﬁcantly lower in the PTLD group, and a
lower absolute count of IgM at day 30 was associated with
PTLD in the multivariate analysis. Although a high IgM level
may be associated with B cell proliferation after HSCT, Liu
et al. [33] recently observed that the reconstitution of B cell
was inhibited at day 30 after haplo-HSCT in recipients who
developed PTLD later. We also observed that the PTLD group
had a signiﬁcantly lower absolute count of CD19þ at day 30
after HSCT. All these results suggested that some antibodies
generated in B cells may be EBV speciﬁc and may effectively
neutralize EBV infectivity; therefore, it can be speculated that
the successful reconstitution of B cells is important for
decreasing the risk of EBV infection and preventing onset of
PTLD post-HSCT. However, the association between the
reconstitution of B cells after haplo-HSCTand PTLD should be
further studied.
Several therapeutic approaches have been recommended
for the treatment of PTLD, including the administration of
rituximab, reduction of immunosuppression, DLI, and the
use of EBV-speciﬁc CTLs. Rituximab is the most important
treatment for PTLD [19]. We observed that patients receiving
rituximab-based therapy have superior clinical outcomes,
which was in accordance with the results of other research
[5]. Because PTLD is usually of donor origin, infusions of
donor leukocytes, which usually contain cytotoxic T cells
presensitized to EBV, might be an effective treatment.
However, data about DLI were limited as DLI was usually
used in combination with other treatment modalities and
the OS was reported as 41.0% [20]. We observed that DLI
could not improve the outcomes of PTLD after unmanipu-
lated haplo-HSCT, and in our previous study, only 3 of 9 PTLD
patients receiving DLI could achieve long-term survival [34].
Adoptive immunotherapy with EBV-speciﬁc CTL may be a
safer and more effective treatment for PTLD [35,36]; how-
ever, a disadvantage with this approach was that the labo-
rious process may take up to 2 to 3weeks to generate CTLs. In
addition, EBV-CTLs were not available tomost patients in our
institution before 2010, and only 3 PTLD patients received
EBV-CTLs in the present study. Thus, the effects of EBV-CTLs
on PTLD after unmanipulated haplo-HSCT should be studied
further. Because most of the PTLD occurred before day 100
after HSCT, tapering of immunosuppression was not always
feasible in consideration of the possibility of severe GVHD
after unmanipulated haplo-HSCT.
This study has several limitations. First, the majority of
PTLD diagnoses were based on clinical features, and only 12
cases were based on histology. A deﬁnitive diagnosis of PTLD
(ie, proven PTLD) requires a tissue biopsy for morphological
analysis, EBV-antigen detection by immunohistocytochem-
istry, and EBV-encoded RNA detection by in situ hybridiza-
tion. However, early treatment is critical because of the rapid
progressive of PTLD. Thus, waiting for histological evidence
may result in missing the best opportunity for curing PTLD.
Therefore, we opted for therapy at the stage of probable
PTLD. As a result, 33 patients had no biopsy before treatment.
Second, we could only identify the association between total
CD8þ T cell reconstitution and PTLD in this retrospective
study. Future study concerning the recovery of EBV-speciﬁc
CD8þ T cells and PTLD may further conﬁrm the association
between immune reconstitution and PTLD after unmanipu-
lated haplo-HSCT. In addition, the retrospective analysis and
the small sample size of PTLD patients also limited our ability
to ascertain the contribution of immune reconstitution to
PTLD and inﬂuenced the accuracy of our results. Last, thehigh numbers of different treatments administered alone,
sequentially, or in association to treat both proven and
probable PTLD were heterogeneous to justify the generic
conclusion of the advantage given by rituximab therapy for
clinical outcomes of PTLD patients. All of these factors
limited the study to an epidemiological description of the
incidence of PTLD after unmanipulated haplo-HSCT. Future
prospective multicenter studies would provide more infor-
mation about the incidence, risk factors, treatments, and
clinical outcomes of PTLD after unmanipulated haplo-HSCT.
In summary, a lower absolute count of CD8þ cells at day
30, a lower count of IgM at day 30, and CMV DNAemia after
HSCT are signiﬁcantly associated with a higher risk of PTLD
after unmanipulated haplo-HSCT. Moreover, rituximab-
based therapy can help to improve the outcomes of PTLD
patients after haplo-HSCT.
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